Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM)

Historical Holders from Q4 2015 to Q3 2025

Symbol: AXSM on Nasdaq
Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 48,932,355
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 37,162,586
Holdings value: $4,512,566,432
% of all portfolios: 0.01%
Number of holders: 349
Number of buys: 188
Number of sells: -141
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
RTW INVESTMENTS, LP	3.1%	-48.3%	$165,312,089	-$153,206,917	1,516,903	-48.1%	RTW Investments, LP	30 Jun 2025

Institutional Holders of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	37,162,586	$4,512,566,432	-$68,301,522	$65,658,318	$66,831,898	$121.45	349
2025 Q2	37,843,872	$3,950,044,159	+$74,087,650	$53,720,608	$52,826,562	$104.39	345
2025 Q1	36,999,749	$4,315,367,902	+$55,229,563	$63,352,057	$87,509,404	$116.63	349
2024 Q4	37,175,235	$3,145,106,906	-$176,513,164	$94,286,924	$149,226,985	$84.61	290
2024 Q3	38,678,079	$3,475,093,026	-$190,434,872	$75,055,284	$78,709,543	$89.87	277
2024 Q2	40,712,369	$3,277,256,100	+$165,407,783	$34,421,800	$28,062,300	$80.50	253
2024 Q1	38,735,398	$3,089,970,732	+$16,979,676	$36,833,840	$31,952,420	$79.80	254
2023 Q4	38,597,370	$3,071,777,083	+$30,855,225	$29,806,775	$54,201,110	$79.59	242
2023 Q3	37,879,928	$2,647,367,402	+$88,702,381	$25,132,444	$39,299,147	$69.89	224
2023 Q2	36,371,724	$2,613,474,662	+$329,094,500	$43,272,816	$76,125,314	$71.86	227
2023 Q1	31,901,760	$1,967,140,427	+$94,141,631	$42,874,992	$50,389,664	$61.68	194
2022 Q4	30,053,540	$2,317,913,385	+$384,566,478	$101,232,718	$126,624,161	$77.13	213
2022 Q3	25,705,114	$1,146,849,855	+$196,048,585	$92,166,000	$62,202,000	$44.62	180
2022 Q2	21,590,557	$826,608,565	+$90,967,881	$77,749,000	$76,598,000	$38.30	164
2022 Q1	19,105,701	$787,305,601	+$28,307,048	$47,170,000	$75,176,125	$41.39	165
2021 Q4	18,632,401	$703,886,639	-$18,569,388	$34,350,000	$101,699,000	$37.78	161
2021 Q3	19,030,753	$625,717,799	-$187,658,523	$49,403,000	$43,867,000	$32.96	165
2021 Q2	22,332,926	$1,506,651,537	-$37,805,529	$51,060,000	$26,027,000	$67.46	172
2021 Q1	22,937,308	$1,299,681,826	-$60,738,349	$46,372,000	$12,524,000	$56.62	181
2020 Q4	23,974,672	$1,951,921,924	-$4,134,242	$45,705,000	$35,602,000	$81.47	178
2020 Q3	24,031,769	$1,711,934,785	-$21,143,954	$54,671,000	$41,811,000	$71.25	171
2020 Q2	24,239,746	$1,992,911,051	+$152,460,166	$59,481,000	$45,188,992	$82.28	188
2020 Q1	22,843,303	$1,344,655,517	+$45,174,721	$56,490,000	$87,945,000	$58.83	163
2019 Q4	22,285,098	$2,303,381,131	+$375,930,983	$93,219,000	$180,248,000	$103.36	168
2019 Q3	18,829,417	$381,131,444	+$8,748,444	$12,531,000	$24,140,000	$20.24	109
2019 Q2	18,265,403	$470,328,087	+$100,449,906	$6,021,000	$13,203,000	$25.75	107
2019 Q1	14,726,528	$209,555,043	+$159,660,613	$6,048,000	$11,696,000	$14.23	64
2018 Q4	3,826,666	$10,790,008	+$478,855	$56,000	$256,000	$2.82	35
2018 Q3	3,533,711	$12,193,010	-$1,993,489	$0	$0	$3.45	33
2018 Q2	4,098,087	$13,112,972	-$296,661	$92,000	$32,000	$3.20	34
2018 Q1	4,234,235	$10,372,895	-$6,125,369	$0	$0	$2.45	35
2017 Q4	5,822,045	$32,606,017	-$1,045,996	$85,000	$207,000	$5.60	33
2017 Q3	6,009,091	$33,278,940	-$2,137,110			$5.55	26
2017 Q2	6,403,943	$35,253,289	-$6,146,767			$5.50	34
2017 Q1	7,754,027	$30,238,589	+$7,294,468			$3.90	47
2016 Q4	6,167,172	$41,627,505	-$969,516			$6.75	41
2016 Q3	6,308,290	$49,689,460	+$4,018,404			$7.88	36
2016 Q2	5,799,374	$43,724,574	+$3,925,477			$7.54	34
2016 Q1	5,260,385	$45,240,000	+$313,024			$8.60	17
2015 Q4	5,216,906	$47,654,000	+$47,654,000			$9.25	11